What is most rewarding?
With a focus on the business side of diagnostics I get most excited about the outcomes. Our tests are covered by many health plans, giving patients access to answers while avoiding surgeries. That means that patients, as a result of our work, have a clear path forward. We are making a real difference.
Real People,
Real Science,
Real Answers.
President and Chief Operating Officer
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.
our impact
The Age
of Evidence
Veracyte's genomic tests have the potential to save billions of dollars each year in unnecessary surgery costs.
Learn More >
Highlighted by National Cancer Institute
NCI highlights lung cancer early detection work behind Percepta in its annual plan
learn more >
Answers That Set New Standards
Veracyte’s CEO named as one of 2017’s Fiercest Women in Life Sciences

learn more >

latest news
news and updates
May 29, 2018
Novel Genomic Sequence Classifier Improves Detection of Benign Thyroid Nodules

learn more >
May 24, 2018
Genomic Markers for Cancer

learn more >
May 17, 2018
Veracyte Launches Early-Access Program for Idiopathic Pulmonary Fibrosis Test

learn more >